Investor Presentaiton
Spotlight on ESR1
~67%-80% of breast cancers
in women are ER+, HER2-1
INVESTOR 20
DAY 23
Emerging
mutation with
high unmet need
fueling
Guardant360
CDx growth
Breast cancer is the
second leading cause of
cancer death in women
~298k new cases and
~44k deaths estimated
in 2023 alone
ER+ tumors have a high
likelihood of developing
ESR1 mutation
ESR1 mutations are present in up to 40%
of ER+, HER2- advanced breast cancers²
ESR1 is an emergent
mutation that develops
after Breast Cancer
treatment occurs
Patients expressing
ESR1 can be put on
a new class of
targeted therapy
ORSERDU
(elacestrant) is the
first FDA approved
ESR1 therapy
Total of 6 ESR1
programs signed
to date with
biopharma partners
GUARDANT™
1 National Cancer Institute https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet; Accessed January 11, 2023;
SEER Database;. 2 Brett, J.O., Spring, L.M., Bardia, A. et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone
receptor-positive breast cancer. Breast Cancer Res 23, 85 (2021). https://doi.org/10.1186/s13058-021-01462-3
55
55View entire presentation